Taiho Oncology, Taiho Pharmaceutical And Cullinan Therapeutics initiate rolling submission of new drug application to US FDA
I'm PortAI, I can summarize articles.
Nov 20 (Reuters) - Cullinan Therapeutics Inc:TAIHO ONCOLOGY, TAIHO PHARMACEUTICAL AND CULLINAN THERAPEUTICS INITIATE ROLLING SUBMISSION OF NEW DRUG APPLICATION TO U.S. FOOD AND DRUG ADMINISTRATION FOR ZIPALERTINIB FOR TREATMENT OF LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER WITH EGFR EXON 20 INSERTION MUTATIONSTAIHO ONCOLOGY INC: ANTICIPATE COMPLETION OF NDA SUBMISSION IN Q1 2026 WITH ASSOCIATED REQUEST FOR PRIORITY REVIEW Source text: Further company coverage:
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments